 |
|
Results from the safety interim analysis of the adjuvant chemoradiotherapy in stomach tumors 2 trial: a multicenter, randomized phase III clinical trial
Se Hoon Park, Jeeyun Lee, Tae Sung Sohn, Do Hoon Lim, Kyoung-Mee Kim, Ji Yeong An, Min Gew Choi, Jun Ho Lee, Jae Moon Bae, Sung Kim, Su Jin Lee, Seung Tae Kim, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang
Precis Future Med. 2019;3(1):24-29. Published online 2019 Mar 13 DOI: https://doi.org/10.23838/pfm.2018.00177
|
|
Citations to this article as recorded by
 Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives
Nikolaos Charalampakis, Sergios Tsakatikas, Dimitrios Schizas, Stylianos Kykalos, Maria Tolia, Rodanthi Fioretzaki, Georgios Papageorgiou, Ioannis Katsaros, Ahmed Adel Fouad Abdelhakeem, Matheus Sewastjanow-Silva, Jane E Rogers, Jaffer A Ajani
World Journal of Gastrointestinal Oncology.2022; 14(1): 181. CrossRef A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆
S.H. Park, D.H. Lim, T.S. Sohn, J. Lee, D.Y. Zang, S.T. Kim, J.H. Kang, S.Y. Oh, I.G. Hwang, J.H. Ji, D.B. Shin, J.I. Yu, K.-M. Kim, J.Y. An, M.G. Choi, J.H. Lee, S. Kim, J.Y. Hong, J.O. Park, Y.S. Park, H.Y. Lim, J.M. Bae, W.K. Kang
Annals of Oncology.2021; 32(3): 368. CrossRef
|